Johnson & Johnson (JNJ), United Therapeutics Corporation (UTHR): 2 Can’t-Miss FDA Rulings Next Week

Normally, our weekly look at what’s going on within the health-care sectors involves a mixture of health-care conferences, FDA panel meetings and decisions, and a plethora of earnings reports. However, as we work our way into a holiday-shortened week thanks to Good Friday, it’s very evident that the upcoming week is going to be dominated by two FDA rulings with few earnings reports and no major conferences on the docket.

J&J for the win?

Johnson & Johnson (JNJ)

With a PDUFA date of Sunday, March 31, the FDA is expected to relay its decision on Invokana, Johnson & Johnson (NYSE:JNJ)‘s Type 2 diabetes drug. Invokana was studied in multiple late-stage trials in patients with an elevated risk for cardiovascular disease and was shown to reduce A1C levels at a much better rate than the placebo. The more interesting tidbit is that one of the placebos in trial was Merck & Co., Inc. (NYSE:MRK)‘s blockbuster drug Januvia, which my Foolish colleague Brian Orelli noted was beaten in every respect by Invokana.

An approval for Invokana would be extremely intriguing, as it’s part of a new class of Type 2 diabetes drugs known as SGLT2 inhibitors. This new drug class works in the kidneys and inhibits the reabsorption of glucose so as to normalize glucose levels. At the moment, only one SGLT2 inhibitor is approved worldwide. That drug is AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY)‘s Forxiga, which is currently approved in Europe. However, it’s worth noting that Forxiga received a complete response letter in the U.S. because of concerns from the FDA about the potential for the experimental drug to cause cancer.

The skinny is that Invokana appears to support approval based on clinical data, but preceding concerns from Forxiga’s rejection hang a cloud over a guaranteed approval. J&J will definitely be a name worth keeping an eye on in the coming week.

Should United Therapeutics shareholders calm down?
Also with a PDUFA date of March 31 (honestly, what was the FDA thinking with these dates?) is United Therapeutics Corporation (NASDAQ:UTHR), with its oral treatment for pulmonary arterial hypertension, known as Treprostinil.

This is actually a new drug application resubmission for United Therapeutics, which received a complete response letter in late October. In that CRL, the FDA questioned the clinical important of the six-minute walking-distance test demonstrated in its Freedom-M study, the inability of United Therapeutics Corporation (NASDAQ:UTHR) to demonstrate an improvement in time to clinical worsening in all of its late-stage trials, and an inability to demonstrate a statistically significant improvement in the 6MWD in two of its Freedom-C trials.

United Therapeutics responded by resubmitting its NDA in mid-February, much more quickly than anyone had expected.This is noteworthy, because it appears that United Therapeutics Corporation (NASDAQ:UTHR) has decided not to run any additional trials. Investors probably shouldn’t expect a huge move either way, but I’d say there’s more downside risk potential at these levels than upside potential if approved.

The article 2 Can’t-Miss FDA Rulings Next Week originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of, and recommends, Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

The 10 Fastest Supercomputers in the World

The 10 Best Countries for Doing Business 2015

6 Most Expensive Fruits In The World

10 Worst Airlines in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!